Pacing for Atrial Fibrillation by Lau, CP
Title Pacing for Atrial Fibrillation
Author(s) Lau, CP
Citation Heart, 2003, v. 89 n. 1, p. 106-112
Issued Date 2003
URL http://hdl.handle.net/10722/43104
Rights Creative Commons: Attribution 3.0 Hong Kong License
doi:10.1136/heart.89.1.106 
 2003;89;106-112 Heart
  
Chu-Pak Lau 
  
 Pacing for atrial fibrillation
 http://heart.bmj.com/cgi/content/full/89/1/106
Updated information and services can be found at: 
 These include:
Data supplement
 http://heart.bmj.com/cgi/content/full/89/1/106/DC1
 "Web-only References"
 References
 http://heart.bmj.com/cgi/content/full/89/1/106#otherarticles
3 online articles that cite this article can be accessed at: 
  
 http://heart.bmj.com/cgi/content/full/89/1/106#BIBL
This article cites 19 articles, 13 of which can be accessed free at: 
Rapid responses
 http://heart.bmj.com/cgi/eletter-submit/89/1/106
You can respond to this article at: 
 service
Email alerting
top right corner of the article 
Receive free email alerts when new articles cite this article - sign up in the box at the
Topic collections
 (700 articles) Arrhythmias 
 (7 articles) Atrial fibrillation 
 (252 articles) Heart Education 
  
Articles on similar topics can be found in the following collections 
 Notes   
 http://www.bmjjournals.com/cgi/reprintform
To order reprints of this article go to: 
 http://www.bmjjournals.com/subscriptions/
 go to: HeartTo subscribe to 
 on 7 November 2006 heart.bmj.comDownloaded from 
Electrophysiology
PACING FOR ATRIAL FIBRILLATION
Chu-Pak Lau
Epidemiological data from the Framingham heart study indicate that the cumulative incidenceof atrial fibrillation (AF) over a 22 year follow up was 2.1% in men and 1.7% in women. Theprevalence of AF increases with age, doubling with each successive decade, and 70% of people
with AF are between 65–85 years old. AF is associated with a three- to fivefold increased risk of
stroke, a threefold increased risk of congestive heart failure, and a significant 1.5- to 1.9-fold mor-
tality risk even after adjusting for underlying cardiovascular conditions. Pacemaker follow up phy-
sicians often have to deal with AF as a co-morbidity. AF may also be associated with brady–tachy
syndrome. A high incidence of AF will be present when we use pacemaker therapy after atrioven-
ticular (AV) nodal ablation for medically refractory AF.
c PHARMACOTHERAPY FOR AF: HOW SUCCESSFUL ARE WE?
Conventional pharmacological treatments includes rate control with AV nodal blockers,
maintenance of sinus rhythm, and anticoagulation. While rate control and anticoagulation is a
recognised treatment strategy, proarrhythmia using class I antiarrhythmic agents to maintain
sinus rhythm remains a concern. A recent study1 has shown that low dose amiodarone, when com-
pared to either sotalol or propafenone, is more efficacious in maintaining sinus rhythm. However,
amiodarone had to be discontinued for cardiac and non-cardiac side effects in 18% of patients,
while 35% of patients still developed AF at 16 months. While newer antiarrhythmic agents may
enhance our success in these refractory cases, the current experience underscores the difficulties of
long term pharmacological treatment to maintain sinus rhythm. Indeed, the preliminary results of
the AFFIRM (atrial fibrillation following investigation of rhythm management) trial did not show
the superiority of rhythm maintenance using drugs over rate control alone (late breaking news,
American College of Cardiology annual meeting, 2002). Thus, the use of pacing, either alone or in
a hybrid fashion with other treatments, has recently gained favour for treating AF.
MECHANISMS OF PACING FOR PREVENTING AF
AF develops as a result of the interaction between the triggers (atrial premature beat (APB)), the
substrate (atrial effective refractory period (AERP), and conduction velocity), and mediation by the
autonomic nervous system. Several groups have examined the changes in sinus rhythm and APB
prematurity in patients developing AF (table 1).2 3 Most data in patients without sinus node disease
(sick sinus syndrome (SSS)) suggest that the prevailing sinus rate before the onset of AF is normal
or only slightly faster than normal. Thus a single rate support algorithm to prevent bradycardia is
unlikely to be effective in suppressing AF in the majority of cases. There are three patterns of APB
induced AF onset: APBs that initiate AF after a pause, and APBs that trigger AF with a closely cou-
pled interval, or after a short-long-short cycle.3 The majority of AF episodes are triggered by closely
coupled APBs that have a coupling interval shorter than those APBs that do not induce AF (table
1). Apart from initiating AF, APBs arising from the pulmonary veins may also act as a perpetuator
of AF. As AF episodes frequently recur within minutes of termination, high rate overdrive pacing
after AF termination may be useful to suppress AF reinitiation.
Atrial electrical remodelling occurs when AF is sustained, leading to a shortening of AERP and
slowing of conduction velocity that promotes AF (AF begets AF). Atrial remodelling is inhomoge-
neous, with more shortening of AERP in the left atrium than the lower right atrium (RA). There is
also prolonged interatrial conduction time and suppressed sinus node function. Pacing, particularly
delivered at multi-sites, may homogenise electrical conduction properties of the atrium and
promote sinus rhythm. For example, distal coronary sinus (CS) pacing has been shown to suppress
APBs from inducing AF by limiting their prematurity at the triangle of Koch, which is a region of
local conduction delay and re-entry. Simultaneous RA and distal CS pacing reduced atrial conduc-
tion delay and increased electrogramwidth at this region and could prevent AF.4 By overdrive atrial
pacing after AF, pacing may avoid AERP dispersion mediated by abrupt cycle length changes,
thereby allowing time for reverse atrial remodelling to occur before AF is reinitiated.
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Very little is written on the role of the autonomic nervous
system on AF mediation. A vagally mediated type of AF has
been described, and overdrive pacing suppresses AF by coun-
teracting the bradycardia.5 A vagolytic effect of pacing the
carotid sympathetic chain has been suggested to suppress cer-
tain types of AF or to control the ventricular rate in animals.
The role of extracardiac stimulation to control AF in humans
remains to be determined.
HOW CAN PACING BE DELIVERED?
Pacing can be delivered either in a passive or an active manner
at a variety of sites (table 2). “Passive pacing” is conventional
pacing to prevent or alter the response to AF. For example, dif-
ferent types of pacing modes have been compared to minimise
the development of AF. Pacing is used in patients who have a
clear bradycardia induced AF. If AF develops in a dual cham-
ber pacemaker (DDD), rapid ventricular response up to the
programmed maximum rate can occur as atrial activities are
tracked. This is handled in modern DDD pacemakers by an
algorithm known as automatic mode switching. When AF is
detected or diagnosed, the pacemaker changes automatically
to a non-atrial tracking mode (for example, DDI or VVI), so
that a rapid ventricular rate does not occur. A clinically proven
strategy to treat medically refractory AF is the use of AV nodal
ablation followed by permanent DDD(R) or VVI(R) pacing.
Both treatments are effectively a type of AF rate control and
pacing does not act on the AF itself. Pacing is often used as an
adjunct to drug treatment: antibradycardia pacing in the case
of successful drug treatment causing sinus bradycardia,
partial control with drugs and bradycardia that requires
backup pacing so that larger doses of drugs can be used, and
intermittent slow rate during AF from drugs used for rate
control. An irregular ventricular rate in AF contributes to
adverse symptoms and haemodynamics, and ventricular pac-
ing delivered at a rate slightly faster than the average
ventricular pacing rate in AF (known as ventricular regulari-
sation pacing) can be used to achieve rate regularisation.
“Active pacing” involves either fixed or dynamic (based on
the current sinus or a sensor mediated rate) overdrive of the
normal sinus rhythm. Active pacing intervention using
algorithms to counteract the mode of APB onset have been
developed. These algorithms can be triggered by the onset of
APBs, with treatment that aims at minimising the changes of
atrial rate.
“Alternative atrial pacing sites” different from the conven-
tional RA appendage or high lateral RA have been evaluated to
modify the underlying substrate. Pacing has also been
delivered from more than one site in the atrium. It is intuitive
that some form of overdrive rate rather than the standard
pacing rate will be necessary to maximise the “dose” of pacing
to these sites, making them a form of active pacing therapy.
Pacing for AF prevention has been applied to the following
patient populations: (1) pacing after AV nodal ablation; (2)
vagally/bradycardia related AF; (3) patients with SSS; (4)
patients with AF with or without sinus bradycardia; and (5)
AF after cardiac surgery. Additionally, pacing methods have
now been used to terminate AF precursors, and to control the
ventricular rate irregularity once AF develops.
PACING AFTER AV NODAL ABLATION
One of the most effective ways to treat the fast and irregular
rate of AF is to use catheter ablation to interrupt the normal
AV conduction system, and leave the patient’s rhythm to be
controlled by a pacemaker. Several studies have documented
the use of this “ablate and pace” strategy in improving symp-
toms, heart failure, and well being of patients over conven-
tional drug treatment.6 In the North American registry that
prospectively collected 156 patients followed up for one year,
sustained improvement in quality of life was observed. Also,
left ventricular ejection fraction was improved in those with a
low ejection fraction (< 45%).
A disadvantage of this strategy is pacemaker dependency,
with the need for replacement and associated morbidity. In
addition, there is a high incidence of progression to
permanent AF, likely to be caused by withdrawal of
antiarrhythmic agents. For example, in one study,6 AF
developed in 24% of patients within six months after “ablate
Table 1 Characteristics of atrial fibrillation (AF) onset2 3
References
Number of
episodes
(patients)
Preceding sinus rate (%) APB coupling interval (ms)
Fast Normal Slow AF No AF
Killip (1965) 18 (14) NA 0.48* 0.68*
Bernett (1970) 32 (8) NA 300 371
Capucci (1992) 168 (20) 15 77 8 412 470
Murgatroyd (1993) 1126 (78) 8.5 82.8 8.7 – –
Mehra (1996) 193 (80) 12 79 9 432 806
Tse (1999) 58 (53) 0 91 9 333 396
*Ratio of atrial premature beat (APB) coupling interval to proceeding sinus cycle length.
Table 2 Types of pacing intervention for atrial
fibrillation
c “Passive pacing”
1. Pacing modes for AF prevention in sinus node disease
AAI (R) v VVI(R)
DDD(R) v VVI(R)
DDD(R) v AAI(R)
2. Ventricular rate control
Automatic mode switching
AV node ablation and pacing
Support pacing for concomitant drug treatment
Ventricular rate stabilisation pacing
c “Active pacing”
Automatic atrial overdrive pacing
Post-ectopic atrial overdrive pacing
Post-AF atrial/overdrive pacing
AF termination
c “Alternative sites”
Bachmann’s bundle region pacing
Low interatrial septal pacing (outside coronary sinus os)
Biatrial endocardial pacing (right atrial and coronary sinus)
Biatrial epicardial pacing (right and left atrium)
Dual site atrial pacing (right atrial appendage and low interatrial
septum)
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and pace”, but in none of the controls in the continued drug
arm. A mortality rate of 15%, with 3% of patients dying
suddenly, was reported. Recent evidence suggests that in the
absence of previous myocardial infarction, congestive heart
failure, and the use of cardiac medications after pacing,
patients after ablate and pace had similar survival to age and
sex matched populations when followed up for three years.
These factors should be considered when prescribing this
treatment for an individual patient.
A DDDR device is commonly prescribed after AV nodal
ablation, together with automatic mode switching to avoid
rapid ventricular tracking of AF. Arguably, because of poor
long term sinus maintenance in this resistant group of
patients, and in patients with persistent AF before ablation, a
VVIR device may be an alternative.
VAGALLY/BRADYCARDIA MEDIATED AF
In some patients, AF episodes typically occur after meals or
exercise, or during sleep and after prolonged sinus pauses. The
use of class Ic agents such as propafenone is the recommended
treatment.β Blockers should be avoided as theymay aggravate
the associated bradycardia. An early study by Coumel and col-
leagues showed in 4/6 patients that atrial pacing prevented
these AF episodes during 5.5 years of follow up, although
almost all patients took disopyramide. This group5 subse-
quently used DDD pacing in 10 patients with SSS in whom AF
onset was related to bradycardia, and 7/10 patients also exhib-
ited interatrial conduction delay that was reversed with higher
rate atrial pacing. By overdrive pacing at a rate slightly above
the mean diurnal rate, this group reported successful control
of AF. These studies suggest that in a small group of patients
in whom AF was clearly related to bradycardia, atrial based
pacing could be effective in preventing AF episodes.
SICK SINUS SYNDROME
AF occurs in a significant proportion of patients with SSS after
pacing. Retrospective studies suggested the use of atrial
pacing in these patients was associated with a lower incidence
of AF compared to ventricular pacing (6.8% v 2.6% annually).
In three prospective randomised studies, AF was also reduced
by atrial pacing. In the Danish study,7 225 patients with SSS
were randomised to either single chamber atrial (AAI) pacing
or ventricular (VVI) pacing, with a follow up of eight years.
The relative risk for AF (0.35 v 0.54), thromboembolic events,
and heart failure were lower with AAI pacing. Similarly, in a
Canadian study8 involving 1474 patients randomised to
VVI(R) pacing and 1094 to atrial based pacing, the annual rate
of AF was reduced from 6.6% to 5.5% with physiological pac-
ing, with a relative risk reduction of AF of 18% by three years.
The effect on AF was only apparent after two years. In the eld-
erly population, DDD systems also improved quality of life and
reduced the progression to chronic AF.9 However, in all of these
studies, conventional pacing is used and a control group is not
possible as all of the involved patients required pacing therapy.
It can be argued that atrial pacing does not actually suppress
AF, rather it is ventricular pacing that is proarrhythmogenic.
Nevertheless, both retrospective and prospective data teach
us that when prescribing pacemaker therapy for SSS, an atrial
based pacing mode is preferred to ventricular pacing to mini-
mise the incidence of AF. The impact of pacemaker
prescription on AF incidence in patients with complete AV
block is less certain, and is the subject of several ongoing
studies (for example, UK PACE). As a high percentage of
patients developed AF even with atrial pacing, some would
advocate prophylactic use of additional strategies (hardware
and software) to combat future AF episodes. These are
described below.
AF WITH OR WITHOUT ASSOCIATED BRADYCARDIA
There are several situations in which a pacemaker is used in
patients with AF. Paroxysmal AF (PAF) is present in about half
of patients with SSS and a third of patients with AV block at
the time of pacing implantation. Antiarrhythmic medications
can depress sinus node function that requires pacing backup,
and this is now increasingly an indication for pacing in many
centres. In refractory cases, some would argue for implanting
a pacemaker first, and delay or avoid AV nodal ablation if AF
can be controlled with a device. Finally, a device to treat AF in
patients without bradycardia has been tested in several clini-
cal studies. The above categories of patients represent the
largest body of data on which pacing therapy has been tested,
either alone or more often in combination with antiarrhyth-
mic medications. Data are also emerging for AF as a
co-morbidity in patients receiving implantable cardioverter-
defibrillators (ICDs) or cardiac resynchronisation devices for
heart failure.
Conventional pacing
In patients with medically refractory PAF pending AV nodal
ablation, the PA3 (atrial pacing periablation for paroxysmal
AF) study randomised patients to either no pacing (DDI at 30
beats/min (bpm)) or to DDIR pacing at a lower rate of 70 bpm,
with continuation of antiarrhythmic drugs.10 Unexpectedly,
pacing did not prolong the time to the first AF recurrence (1.9
days v 4.2 days with no pacing, p = NS). In fact, pacing was
associated with a trend for higher AF burden. Potential
limitations in this study are the use of a pacing mode (DDIR)
that did not guarantee AV synchrony, the lack of an overdrive
algorithm to ensure a high percentage of atrial pacing (the
atrium was paced in only 67% in this study), the use of atrial
pacing at the conventional single site at the RA appendage,
and the relatively short follow up (10 weeks).
The PA3 study suggests that in patients with medically
refractory AF who do not have bradycardia, conventional
atrial pacing at 70 bpm in the short term is not effective in
preventing AF.
Atrial overdrive
In patients with conventional pacing with a DDDR pacemaker,
it is simple to just increase the backup rate to suppress AF.
Ward and colleagues11 randomised 18 patients with PAF and
SSS to a backup rate of 60, 75, and 90 bpm, each for a two
month period to test this hypothesis. While the percentage of
atrial pacing increased by 44%, 57.5%, and 73.5%, respectively,
Abbreviations
AERP: atrial effective refractory period
AF: atrial fibrillation
APB: atrial premature beat
ATP: antitachycardia pacing
AV: atrioventricular
CS: coronary sinus
ERAF: early reinitiation of atrial fibrillation
ICD: implantable cardioverter-defibrillator
PAF: paroxysmal atrial fibrillation
RA: right atrium
SSS: sick sinus syndrome
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the incidence of AF (as defined by mode switching episodes)
were not affected. On the other hand, one third of the patients
developed angina when programmed to 90 bpm. It seems that
the use of a high fixed lower rate to overdrive the atrium is not
effective and is poorly tolerated.
If a fixed rate is ineffective, perhaps an algorithm to
automatically overdrive the atrium may be more effective. In
the Continuous Atrial Pacing algorithm (Medtronic Inc, Min-
neapolis, Minnesota, USA), for each P wave sensed the device
shortens the atrial escape interval (for example, 30 ms) up to
a programmable consistent overdrive rate limit to ensure atrial
pacing. In 15 patients with such an algorithm, the percentage
of atrial pacing is significantly increased from 57% to 86%, the
incidence of APBs is reduced, and a trend to a lower incidence
of mode switching and fewer AF symptoms was observed.12
These benefits were not associated with a change in the mean
atrial rate during the day or at night time.
The Dynamic Atrial Overdrive (DAO, St Jude, Minneapolis,
USA) algorithm has been tested in a randomised study in 250
patients—the atrial dynamic overdrive pacing to treat
paroxysmal AF study (ADOPT A study, late breaking news,
North American Society of Pacing and Electrophysiology
Society meeting, 2001). Preliminary results suggest that over-
drive pacing was more effective than conventional pacing in
reducing AF burden (60% v 45% suppression of baseline AF
burden after six months of pacing) and improved symptoms
of AF. The algorithm was well tolerated. Thus if there is
evidence of AF in patients with pacemakers, it is reasonable to
activate an automatic atrial overdrive mechanism if available
that varies its rate according to the prevailing sinus rhythm
rate. Further results are pending to see if the beneficial effect
of atrial overdrive is algorithm specific.
Algorithms specific to APB/AF triggers
Experience with algorithms that overdrive the atrium when
APBs occur suggests these are effective in reducing APB
frequency, but not the overall AF episodes. After spontaneous
or defibrillation-achieved AF termination, AF could occur in
up to 34% of patients. Again, closely coupled ectopy is the
cause of early reinitiation of AF (ERAF), which limits long
term sinus rhythm maintenance. Tse and colleagues13 tested,
in a randomised manner, the use of atrial overdrive pacing
post-defibrillation in suppressing APBs and ERAF in 12
patients with reproducible ERAF. Pacing at 400 ms and
300 ms were equally effective in preventing ERAF (42%), or
delaying its onset (58%). APB density was reduced from 16.4/
min to 3.4/min with pacing, and the mean coupling interval of
these APB to sinus rhythm was significantly prolonged (from
398 ms to 420 ms) by pacing (fig 1). The design of the “post-
mode-switch” overdrive (Medtronic Inc) is specifically based
on this observation, although the optimal pacing rate and
duration of pacing remain uncertain.
A variety of other algorithms such as rate smoothing post-
APBs have been instrumented in different devices. There are
as yet little data on their efficacy on top of automatic atrial
overdrive pacing. In combination with antitachycardia pacing
(ATP), these algorithms can contribute to reduction of AF
burden (see below).
Alternative and multiple site atrial pacing
These include Bachmann’s bundle region/interatrial septal
pacing, biatrial pacing (RA appendage and distal CS), and
dual site atrial pacing (RA appendage and low atrial septum).
Bachmann’s bundle region or interatrial septal pacing
The existence of the Bachmann’s bundle is controversial.
Nevertheless, acute testing suggests that pacing at the anterior
superior interatrial septum leads to rapid conduction to either
atrium, and may be a suitable site to suppress AF. Bailin and
colleagues14 randomised 120 patients with a mean age of 70
years to either RA appendage or Bachmann’s bundle region
pacing. All patients had SSS and a history of paroxysmal AF,
and half had a prior AV nodal ablation. The Bachmann’s bun-
dle region was achieved by positioning an actively fixed lead in
the highest point in the interatrial septum (using the fluoro-
scopic left anterior oblique view), with the lead pointing ante-
riorly in the right anterior oblique view (fig 2A). Compared to
RA appendage pacing, pacing in the Bachmann’s bundle
region significantly delayed the onset of permanent AF (75%
v 47% at one year, p < 0.05). Interestingly, in most cases per-
manent AF developed within two months after pacing in the
RA appendage group, and thereafter the onset of permanent
AF was similar between the two groups. Both acute and long
term atrial thresholds were similar between the two pacing
sites. Bachmann’s bundle region pacing was also associated
with a shortened P wave duration. These results are encourag-
ing. However, there was a high incidence of AF in the RA
appendage group, and withdrawal of antiarrhythmic drugs
Figure 1 Pacing in the suppression of early reinitiation of atrial
fibrillation (AF). (A) AF occurred at baseline by an early atrial
premature beat (APB) occurring in the left atrium (earliest recording
at the distal CS: CS9–10). (B) Atrial pacing at 500 ms prevented AF
from recurring. The coupling interval of the APB was also prolonged
from 210 ms to 240 ms, which did not reinitiate AF. CS, coronary
sinus; HIs, His bundle; RA, right atrium; RV, right ventricle.
Reproduced from Tse et al13 with permission.
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might have influenced the outcome of this study. The proxim-
ity of the site to the aortic arch is a potential concern, although
no complication related to the aorta was observed in this
study. AF burden was not measured. Several studies are now
underway to test the incremental benefit of automatic atrial
overdrive in suppressing AF burden in the high septal region.
Padeletti and colleagues15 reported the result of pacing at
the low interatrial septum. This site was chosen as it is near
the triangle of Koch (an area of slow conduction), and was
approached by using a screw-in lead above the CS os. They
studied 46 patients with paroxysmal AF, randomised to either
RA appendage or low septal pacing. Either pacing mode
reduced AF compared to pre-implantation frequency, but low
interatrial septal pacing was superior to RA appendage pacing
in reducing AF burden over a three month period. Again, P
wave duration was significantly reduced compared to that in
sinus rhythm.
Taken together, these studies suggest that pacing at the
interatrial septum (high or low) shortens the P wave duration,
and reduces the incidence of AF compared to the RA append-
age site. At least in the short and medium term, the right
interatrial septal site appears to be as stable and safe as the
conventional appendage position. These sites may be an alter-
native pacing site for AF control in patients with SSS and AF
if the issues of complexity in implantation and long term lead
stability can be solved.
Biatrial pacing
Daubert and his colleagues pioneered biatrial pacing by using
a CS bipolar lead to achieve left atrial pacing simultaneously
with conventional RA pacing. They tested the efficacy of
biatrial pacing in patients with either prolonged P wave dura-
tion (> 120 ms) or interatrial conduction time (> 100 ms). In
a group of 86 patients with atrial tachyarrhythmias, they were
able to reduce P wave duration (from mean (SD) 187 (29) ms
to 160 (14) ms), and maintained sinus rhythm in 64% (with
33% free from any episode of AF).16 However, in a multicentre
European trial (the SYNBIPACE (synchronous biatrial pacing
for reduction of paroxysmal/permanent AF) study), such a
benefit in AF suppression was not reproduced. Thus this tech-
nique may be applicable to select patients with long interatrial
conduction delay, and can also possibly contribute to better
left heart AV interval programming and haemodynamic ben-
efits. However, double sensing of A and V electrograms in the
CS can be a problem, and special blanking is required. There is
concern (as with biventricular pacing for heart failure) over
the stability of the CS lead, and the ease with which lead
extraction can be effected.
Dual site atrial pacing
Delfaut and colleagues pioneered the use of RA appendage to
RA low septal pacing (just outside the CS os) in suppressing
AF17 (fig 2B). Thirty patients with drug refractory sympto-
matic AF and documented primary or drug induced bradycar-
dia underwent a crossover study to assess: (1) if pacing was
useful to prevent AF compared to pre-implant history; (2) if
single site (RA appendage or CS os pacing) were different; and
(3) if dual site pacing had additional benefit to single site pac-
ing. A fixed rate overdrive was used and event recorder docu-
mented first AF recurrence was used as the primary end point.
The mean arrhythmia-free interval was increased from mean
(SD) of 9 (10) days before implant, to 143 (110) days during
single site periods, and to 195 (96) days during dual site
crossover period. The authors did not find any difference
between single site pacing at the RA appendage or CS os pac-
ing in suppressing AF. Significantly, this study also docu-
mented long term safety of dual site pacing up to three years,
with no case of CS os lead dislodgement after patient
discharge from hospital, compared to a rate of dislodgement of
up to 8% in dual site pacing. Although uncontrolled, the long
term efficacy of maintaining sinus rhythm was 78% at one
year and 56% at three years, which was remarkable in a very
refractory group of patients. The limitations of this study were
the lack of an unpaced controlled group, frequent crossover
with potential carryover effect, and the need for antiarrhyth-
mic medications to maintain sinus rhythm.
We have specifically addressed the use of dual site atrial
pacing in patients with paroxysmal AF without conventional
Figure 2 Lateral chest radiographs.
(A) High interatrial septal pacing near
the Bachmann’s bundle region
(RAbb). (B) Dual site atrial pacing
with one atrial lead in the appendage
(RAap) and the other outside the
coronary sinus os (CSos). RV, right
ventricular electrode.
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indication for pacing, using pacemakers with the Continuous
Atrial Overdrive algorithm.18 Twenty two patients who had AF
recurrence despite sotalol treatment underwent randomised
crossover periods of 12 weeks with either pacing on (plus
sotalol) or continuation of sotalol only. The end points were
event recorder documented AF recurrence and pacemaker
memory of AF burden. Dual site atrial pacing increased the
percentage of atrial pacing (13 (18)% to 80 (30)%), reduced
the number of APBs (from 8265/day to 2740/day), prolonged
the time to the first documented AF (symptomatic or asymp-
tomatic), and reduced AF burden (45 (34)% to 22 (29)%).
Pacing reduced the risk of AF recurrence by 3.2 times. There
was significant change in some measures of quality of life, but
no overall change in AF symptoms. The DAPPAF (dual site
atrial pacing for the prevention of AF) study prospectively
randomised and crossed over patients between dual site and
RA appendage pacing and support pacing in patients with PAF
and pacing indications. The preliminary results suggested that
dual site pacing with overdrive in combination with either
class I or III antiarrhythmic agents was better tolerated and
more effective in AF prevention than overdrive RA pacing or
support pacing. Several other studies have also reported on the
efficacy of dual site pacing.
Taken together, these trials indicate that pacing has an
effect on the burden of AF in patients with or without the need
of a pacemaker. Automatic atrial overdrive pacing is necessary
for pacing to be effective, and multisite pacing may have an
incremental benefit. However, the use of multiple leads (with
their complexity of implantation and programming) should
probably be reserved for those with AF of moderate severity.
Use of a β blocker may provide an incremental benefit. Uncer-
tainty remains as to the clinical predictors for a favourable
response to dual site atrial pacing.Neither the P wave duration
nor interatrial delay before pacing were predictive of an effec-
tive outcome.
AF AFTER CARDIAC SURGERY
Approximately 20% of patients developed AF after bypass sur-
gery. The causes are multifactorial, andmay include the effects
of cardiac bypass, changes in sympathetic tone, and postop-
erative infection. The development of AF is associated with an
increase in stroke, heart failure, and length of hospital stay,
which substantially increase management cost. β Blockers
and amiodarone have been shown to be effective prophylactic
agents for AF, but AF still developed in up to 30% of these
patients despite amiodarone pre-treatment.
After cardiac surgery, epicardial pacing placement is often
routine for support pacing, and it is of interest to assess if pac-
ing may have effects on postoperative AF. Several studies have
recently examined the effect of pacing (in addition to β
blocker treatment) in suppressing postoperative AF. Fan and
colleagues19 randomised 132 patients to biatrial, RA, and left
atrial pacing or control. Manual overdrive atrial pacing was
performed for five days, at 10 bpm above the intrinsic rate up
to 90 bpm. Only biatrial pacing reduced the development of
sustained AF (42% in control v 12.5% during pacing), whereas
single site pacing had no effect. The beneficial effect was
attributable to a larger reduction of P wave dispersion during
biatrial pacing compared with single site pacing or control,
and only patients with AF prevention had a reduction in P
wave duration. Postoperative intensive care stay and the asso-
ciated cost were reduced. Several studies have since reported
the efficacy of pacing, particularly biatrial pacing, in suppress-
ing postoperative AF, with the left atrial lead in the posterior
atrium. The convenience and ease of instrumentation of
biatrial pacing is a strong incentive to apply this technique to
most patients after postoperative cardiac surgery.
ANTITACHYCARDIA PACING
While the short excitable gap during sustained AF does not
lend itself to pacing termination, ATP has several potential
mechanisms to reduce AF burden. Many episodes of AF
degenerate from atrial tachycardia or flutter, and early termi-
nation of these precursor rhythms may prevent AF from
becoming established. Conversely, after antiarrhythmic agents
(especially class Ic drugs), AF may be converted to flutter or a
slower atrial tachycardia that can be terminated. It is logical to
consider ATP in an implanted device to terminate these AF
related rhythms.
Atrial ATP (burst, ramp, and 50 Hz stimulation) are now
available in some ICDs and pacemakers. Several groups have
reported on the efficacy of ATP, ranging from 33–86%, depend-
ing on the organisation of AF (fig 3A). Interestingly,
“organised” rhythms were encountered in nearly half of all
recorded episodes in patients with a clinical diagnosis of par-
oxysmal AF, suggesting that ATP may have a role in these
patients. Twenty five per cent of patients with ICDs have
associated AF. Friedman and colleagues20 randomised 52/269
patients with a combined atrial and ventricular ICD to either
ATP, atrial defibrillation, and preventive pacing versus only
ventricular ICD function, each for a three month randomised
period. Atrial therapies significantly reduced AF burden from
Figure 3 (A) Pacemaker stored atrial electrogram (EGM) and
marker annotation showing an episode of spontaneous “organised”
atrial tachyarrhythmia which was sensed (TS) (upper panel), and
subsequently detected as fibrillation (FD) and terminated by
antitachycardiac pacing (lower panel) (AT 500, Medtronic). AP,
atrial pacing; VS, ventricular sensing. EGM not available during AP
(B) Telemetry recording of the AF history of the same patient
indicating a decreasing trend of AF burden and AF episodes.
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58.5 to 7.8 h/month. The efficacy of ATP for terminating slower
and faster atrial tachyarrhythmias were 62% and 49%, respec-
tively. While encouraging, these studies are limited by
frequent patient exclusion and insufficient randomisation,
and it is uncertain if burden reduction was related to pacing
prevention or to ATP itself. Thus, in the absence of a well con-
trolled randomised trial, it is uncertain whether ATP works or
may be proarrhythmogenic.
VENTRICULAR RATE STABILISATION
Apart from a rapid rate, irregularity in AF contributes to
abnormal cardiac haemodynamics. By pacing the RV at a rate
slightly faster than the mean ventricular rate of AF, it is possi-
ble to suppress shorter cycles and regularise the rate. This has
been attributed to retrograde concealed activation in the AV
node. Acute testing suggested that rate regularisation pacing
can regularise AF at rest and to some extent during exercise.
Ventricular rate stabilisation algorithms have been developed
by several manufacturers. Clinical benefit in ambulatory
patients remains to be confirmed, and the long term effect on
left ventricular function because of pacing needs to be consid-
ered.
FUTURE PERSPECTIVES
Pacing either in the treatment or prevention of AF should not
be an isolated therapy. AF is a heterogeneous disease, and a
hybrid approach is the standard. For example, concomitant
antiarrhythmic medications are commonly used with pacing.
Radiofrequency ablation can eliminate pulmonary vein
ectopic foci for AF or modify the atrial substrate, and atrial
defibrillation can further enhance the maintenance of sinus
rhythm. The various types of hybrid therapy are under evalu-
ation.
An important development in device therapy for AF is the
ability to measure the total amount of AF (AF burden) that
can be confirmed with stored atrial electrograms (fig 3B). This
is a more accurate assessment of AF than the time to the first
recurrence of AF itself. In addition, device based AF recording
gives the clinician the possibility of objectively measuring the
severity of AF, and may become a useful guide to assess inter-
ventional procedures, the need for anticoagulation, and to
understand the symptomatology of AF itself.
CONCLUSION
Ablation and pacing for medically refractory AF is clinically
proven, and is an effective symptomatic therapy. In patients
with SSS, an atrial based pacemaker should be prescribed to
reduce future episodes of AF. An automatic atrial overdrive
algorithm appears to be effective in reducing symptomatic AF.
Dual site right atrial pacing, in the presence of overdrive and β
blocker, confers additional benefit to single site pacing.
Epicardial biatrial pacing is a useful technique to reduce the
incidence of AF complicating cardiac surgery.While automatic
mode switching and ventricular rate stabilisation will become
programmable features of modern pacemakers, the role of ATP
in patients with AF remains to be confirmed. It is likely that
pacing efficacy will be enhanced when combined with
strategies such as ablation, pharmacotherapy, and defibrilla-
tion.
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